Loading page…

Godavari Drugs Ltd (GODAVARI) · mywealthgrid

About

Godavari Drugs Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹119 Cr

P/E

28.9×

P/B

1.6×

Dividend yield

ROE

6.9%

ROCE

9.4%

Debt / equity

1.01

OPM

9.7%

EPS (TTM)

₹4.1

Book value

₹74.8

52-week high

₹130.2

52-week low

₹70.2

₹118.1+36.5%1Y

Beta

0.6

Damps index moves

Volatility (1y)

56.3%

Annualised, daily returns

RSI (14)

47.6

Neither overbought nor oversold

Rel. strength (1y)

30.9%

Ahead of the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Outperformed the universe by 30.9% over 1 year

Cons

−Low return on equity of 10.9% (3-yr avg)
−Profit declined 0.2% a year over the last 5 years
−Revenue shrank over the last 5 years (-2.9% a year)
−Promoter holding fell 12.4 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

50/100

Business quality: 19
Growth: 52
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	71	81	64	84	96	123	161	160	157	113	106
COGS	—	—	-49	-65	-77	97	130	128	121	82	78
Gross profit	—	—	—	—	—	26	31	32	36	32	28
	67	76	110	143	166	16	19	22	23	20	18
	4	5	4	5	6	10	11	10	13	12	10
OPM %	5.9%	5.6%	5.9%	6.6%	6.3%	8%	7%	6.2%	8.5%	10.4%	9.7%
Depreciation	—	—	—	1	1	1	2	2	2	2	2
Interest	2	3	2	3	3	3	3	4	5	5	4
	0	1	1	0	0	0	0	1	1	1	1
Profit before tax	2	3	1	2	2	6	7	5	7	6	5
Tax	1	1	0	1	0	2	2	1	1	1	1
Tax %	38.5%	33.2%	37.4%	30.9%	12.7%	27.7%	25.4%	23.3%	19.8%	22.2%	19.2%
	1	2	1	1	2	4	5	4	6	4	4
PAT margin %	1.9%	2.3%	1.3%	1.5%	2.1%	3.4%	3.3%	2.4%	3.5%	3.9%	3.9%
EPS (₹)	1.8	2.4	1.1	1.6	2.7	5.5	7	5	7.4	5.8	5.4
EPS adjusted (₹)	—	—	—	—	—	5.5	7	5	7.4	5.8	4
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	8	8	8	8	8	10
Reserves	17	22	26	31	36	66
	28	20	34	56	62	76
	39	51	55	40	38	48
Total equity & liabilities	91	101	121	135	143	200
	22	26	25	27	33	30
CWIP	1	0	9	18	30	57
Investments	0	0	0	0	0	0
	68	75	87	90	81	114
Total assets	91	101	121	135	143	200

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1	11	13	18	11	1
	-1	-5	-9	-13	-20	-26
	0	-6	-4	-6	8	37
Net cash flow	0	1	1	-0	-0	12
Free cash flow	-0	6	4	5	-9	-26
CFO / Operating profit %	13.5%	99.4%	133.3%	138.4%	94.7%	7.1%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	21.3%	19%	19.8%	22.9%	28%	26.8%
EBITDA margin %	6.6%	6.3%	8%	7%	6.2%	8.5%	10.4%	9.7%
EBIT margin %	5.2%	5.1%	7%	6%	5%	7.2%	8.3%	7.4%
PAT margin %	1.5%	2.1%	3.4%	3.3%	2.4%	3.5%	3.9%	3.9%
Working capital
Receivable days	—	—	134	126	132	138	136	150
Inventory days	—	—	55	28	57	62	125	217
Payable days	—	—	111	121	132	96	128	163
NWC days	—	—	78	33	58	105	133	204
Leverage
Current ratio	—	—	1.34	1.29	1.18	1.08	1.08	1.31
Debt to EBITDA	—	—	2.86	1.8	3.38	4.18	5.21	7.41
Debt to equity	—	—	1.15	0.69	1	1.43	1.42	1.01
Interest coverage	1.6	1.8	2.7	3.5	2.2	2.4	2.2	2.2
Asset turnover	—	—	1.35	1.59	1.31	1.16	0.79	0.53
Return ratios
Return on assets %	—	—	4.5%	5.2%	3.1%	4.1%	3.1%	2%
Return on capital employed %	—	—	22.2%	23.4%	18.9%	23.7%	16.9%	9.4%
Return on equity %	—	—	16.9%	17.7%	11.3%	14.2%	10.1%	5.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	53.16%	53.16%	53.16%	53.16%	52.63%	52.63%	52.63%	52.63%	52.61%	52.61%	40.23%	40.23%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	2.47%	2.74%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	46.34%	46.34%	46.34%	46.34%	46.87%	46.87%	46.87%	46.87%	46.89%	46.89%	57.3%	57.03%
No. of shareholders	—	—	—	—	—	—	—	—	7,720	7,483	7,300	6,722

Promoter holding down 12.93 percentage points since Sep 2023.

17 deals · 5 Jan 2022 – 16 Jan 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
16 Jan 2026	TRADELINK EXIM INDIA PVT LTD	Bulk	BSE	Buy	39,217	₹98.88	₹0.39 Cr
26 Aug 2024	MADHUSUDHAN GUNDA	Bulk	BSE	Buy	40,000	₹106.20	₹0.42 Cr
26 Aug 2024	MADHUSUDHAN GUNDA	Bulk	BSE	Sell	33,892	₹112.00	₹0.38 Cr
15 Jun 2023	PRASHANT SHRIMAL	Bulk	BSE	Sell	41,833	₹93.52	₹0.39 Cr
6 Jun 2023	PRASHANT SHRIMAL	Bulk	BSE	Sell	1,55,167	₹88.00	₹1.37 Cr
6 Jun 2023	MOHIT JAJU	Bulk	BSE	Buy	70,000	₹87.99	₹0.62 Cr
6 Jun 2023	SUSHMA KAKANI	Bulk	BSE	Buy	70,000	₹88.00	₹0.62 Cr
19 Dec 2022	YUGA STOCKS AND COMMODITIES PRIVATE LIMITED .	Bulk	BSE	Buy	45,000	₹75.78	₹0.34 Cr
19 Dec 2022	YUGA STOCKS AND COMMODITIES PRIVATE LIMITED .	Bulk	BSE	Sell	45,000	₹75.76	₹0.34 Cr
19 Dec 2022	ARHAM SHARE PRIVATE LIMITED	Bulk	BSE	Buy	40,564	₹75.80	₹0.31 Cr

1–10 of 17

1 / 2

Mr. GHANSHYAM JAJUNon-Executive - Non Independent Director-Chairperson related to Promoter
Mr. MUKUND KAKANIExecutive Director-MD
Mr. MOHIT JAJUExecutive Director
Mr. MAHENDRA UDAY BHALERAONon-Executive - Independent Director
Mr. DINESH UDPANon-Executive - Independent Director
Mrs. SHILPA BUNGNon-Executive - Independent Director
Mr. Venkatesh AchantaCompany Secretary

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Godavari Drugs Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results14 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

16 announcementsExport CSV

21 Sept 2026, 10:46 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

3 Sept 2026, 2:08 pmCompany Update

Intimation Of Dispatch Of Physical Letters Pursuant To Regulation 36(1)(B) Of The SEBI (LODR) Regulations

General PDF

3 Sept 2026, 10:55 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

1 Sept 2026, 4:54 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

1 Sept 2026, 4:48 pmAGM/EGM

Godavari Drugs Ltd - 530317 - 39Th AGM To Be Held On 25Th Sep 2026 At 11.00 A.M. Through Video Conferencing

AGM PDF

1 Sept 2026, 4:45 pmCorp. Action

38Th AGM To Be Held On 25.09.2026 - Book Closure - 19.09.2026 - 25.09.2026 (Both Days) And Evoting, Cutoff Date.

Book Closure PDF

1 Sept 2026, 11:01 amCompany Update

Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association

Amendments to Memorandum & Articles of Association PDF

31 Aug 2026, 6:56 pmOthers

Board Meeting Outcome for Outcome Of Board Meeting Held On 31.08.2026 - Alteration Of The Main Objects Clause III(A) Of The Memorandum Of Association And Approval Of Revised Notice Of The 38Th Annual General Meeting

Outcome without intimation PDF

Date	Category	Subject	Filing
21 Sept 2026, 10:46 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
3 Sept 2026, 2:08 pm	Company Update General	Intimation Of Dispatch Of Physical Letters Pursuant To Regulation 36(1)(B) Of The SEBI (LODR) Regulations

Loading announcements…

Godavari Drugs Ltd

Godavari Drugs Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

1

Announcements

No fund holdings on record

Not in the F&O segment

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Godavari Drugs Ltd

Godavari Drugs Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

No fund holdings on record

Not in the F&O segment

Board meetings1

Ratio timeline

Announcements

Annual reports

Quarterly record

Bulk & block deals

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

1

1